Strategies for Anticancer Treatment in p53-Mutated Head and Neck Squamous Cell Carcinoma.

Bi-He Cai, Chia-Chi Chen, Yu-Te Sung, Yu-Chen Shih, Ching-Feng Lien

Abstract read

In one paragraph

Article in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Bi-He CaiSchool of Medicine, I-Shou University, Kaohsiung City 82445, Taiwan.ORCID 0000-0003-4226-6096

Chia-Chi ChenSchool of Medicine, I-Shou University, Kaohsiung City 82445, Taiwan.ORCID 0000-0002-4905-3408

Yu-Te SungDepartment of Plastic Surgery, E-Da Hospital, Kaohsiung City 82445, Taiwan.

Yu-Chen ShihDepartment of Otolaryngology-Head and Neck Surgery, E-Da Hospital, Kaohsiung City 82445, Taiwan.

Ching-Feng LienSchool of Medicine, I-Shou University, Kaohsiung City 82445, Taiwan.ORCID 0000-0001-8245-5495

Funding

I-Shou University and E-Da Medical Con-sortium Legal Person Research Cooperation Project ISU-113-IUC-10

6 · The paper itself

Abstract

This Opinion summarizes the strategies for anticancer treatment in p53-mutated head and neck squamous cell carcinoma (HNSCC). It examines six strategies for anticancer treatment in p53-mutated HNSCC: 1. direct reactivation of mutated p53; 2. activation of p63; 3. activation of p73; 4. degradation of mutated p53; 5. blocking the p53-regulated oncogenic microRNA; and 6. blocking the p53-regulated oncogenic long non-coding RNA. Since HNSCC has a high p53 mutation rate compared to other types of cancers, these strategies for combating p53-mutated HNSCC may prove useful for generating new ideas or methods for developing treatments for other cancers with p53 mutations. This article also explores other factors that may impact the effectiveness of anticancer therapies in p53-mutated HNSCC.

Indexed as

head and neck cancerHNSCCmutationp53

Identifiers

PMID40426992

DOI10.3390/biomedicines13051165

PMCPMC12108584

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.